An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC).-MedSci.cn

An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC).

Raghav, KPS; Yoshino, T; Taniguchi, H; Tejpar, S; Vogel, A; Wainberg, ZA; Yamaguchi, K; Kanai, M; Liu, YL; Mekan, S; Pudussery, G; Qiu, Y; Kopetz, S

JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (3):

科室
- - 订阅+
  - 更多科室
工具
服务